| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $519,384 | 12 | 100 |
| 5AM Partners VII, LLC | 10 percent owner | 0 | $0 | 6 | $259,692 | $-259,692 |
| Schwab Andrew J. | 0 | $0 | 6 | $259,692 | $-259,692 |
Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in …
Over the last 12 months, insiders at Skye Bioscience, Inc. have bought $0 and sold $519,384 worth of Skye Bioscience, Inc. stock.
On average, over the past 5 years, insiders at Skye Bioscience, Inc. have bought $8.27M and sold $2.26M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 450,000 shares for transaction amount of $4.5M was made by 5AM Partners VII, LLC (10 percent owner) on 2024‑03‑13.
| 2026-09-23 | Sale | Schwab Andrew J. | 4,528 0.0922% | $1.61 | $7,290 | -11.67% | ||
| 2026-09-23 | Sale | 5AM Partners VII, LLC | 10 percent owner | 4,528 0.0922% | $1.61 | $7,290 | -11.67% | |
| 2026-09-22 | Sale | Schwab Andrew J. | 28,700 0.6107% | $1.65 | $47,355 | -6.73% | ||
| 2026-09-22 | Sale | 5AM Partners VII, LLC | 10 percent owner | 28,700 0.6107% | $1.65 | $47,355 | -6.73% | |
| 2026-09-16 | Sale | Schwab Andrew J. | 33,892 0.8668% | $1.91 | $64,734 | -5.59% | ||
| 2026-09-16 | Sale | 5AM Partners VII, LLC | 10 percent owner | 33,892 0.8668% | $1.91 | $64,734 | -5.59% | |
| 2026-08-20 | Sale | Schwab Andrew J. | 7,700 0.025% | $0.32 | $2,464 | -25.00% | ||
| 2026-08-20 | Sale | 5AM Partners VII, LLC | 10 percent owner | 7,700 0.025% | $0.32 | $2,464 | -25.00% | |
| 2026-08-19 | Sale | Schwab Andrew J. | 68,140 0.2218% | $0.35 | $23,849 | -31.43% | ||
| 2026-08-19 | Sale | 5AM Partners VII, LLC | 10 percent owner | 68,140 0.2218% | $0.35 | $23,849 | -31.43% | |
| 2026-08-18 | Sale | Schwab Andrew J. | 300,000 0.9036% | $0.38 | $114,000 | -41.46% | ||
| 2026-08-18 | Sale | 5AM Partners VII, LLC | 10 percent owner | 300,000 0.9036% | $0.38 | $114,000 | -41.46% | |
| 2025-08-22 | Sale | Schwab Andrew J. | 170,449 1.6463% | $3.42 | $582,936 | -74.81% | ||
| 2025-08-22 | Sale | 5AM Partners VII, LLC | 10 percent owner | 170,449 1.6463% | $3.42 | $582,936 | -74.81% | |
| 2025-08-21 | Sale | Schwab Andrew J. | 60,956 0.6146% | $3.57 | $217,613 | -76.65% | ||
| 2025-08-21 | Sale | 5AM Partners VII, LLC | 10 percent owner | 60,956 0.6146% | $3.57 | $217,613 | -76.65% | |
| 2024-11-18 | Sale | DHILLON PUNIT | Chief Executive Officer | 82,546 1.1633% | $4.99 | $411,905 | -39.04% | |
| 2024-11-18 | Sale | Grayson Paul A. | director | 86,244 1.2154% | $4.99 | $430,358 | -39.04% | |
| 2024-11-18 | Sale | ARSENAULT KAITLYN | Chief Financial Officer | 43,026 0.6064% | $4.99 | $214,700 | -39.04% | |
| 2024-11-18 | Sale | Diep Tuan Tu | Chief Development Officer | 19,489 0.2747% | $4.99 | $97,250 | -39.04% |
| 5AM Partners VII, LLC | 10 percent owner | 0 0% | $0 | 2 | 10 | <0.0001% |
| Emerald Health Sciences Inc. | 10 percent owner | 123923501 2798.8384% | $151.19M | 1 | 1 | |
| DHILLON PUNIT | Chief Executive Officer | 329823 7.4491% | $402,384.06 | 1 | 2 | |
| McLaughlin Gerald W. | director | 10000 0.2259% | $12,200.00 | 1 | 0 |
$6,974,678 | 45 | -14.98% | $4.63M | |
$29,645,465 | 28 | 8.09% | $6.48M | |
$63,749,694 | 24 | -12.24% | $6.4M | |
$287,718 | 15 | -41.45% | $5.68M | |
$1,246,170 | 12 | 65.67% | $5.42M |
| Increased Positions | 21 | +24.71% | 242,806 | +1.22% |
| Decreased Positions | 33 | -38.82% | 4M | -20.09% |
| New Positions | 15 | New | 211,392 | New |
| Sold Out Positions | 23 | Sold Out | 3M | Sold Out |
| Total Postitions | 73 | -14.12% | 16M | -18.87% |